Evidence-based coverage of GLP-1 agonists, metabolic peptides, and weight loss science for Australian adults.
50 articles · sorted by most recent
Eli Lilly's orforglipron is the first non-peptide oral GLP-1 agonist with full Phase 3 data. This guide covers the ATTAIN-1 obesity trial, the ACHIEVE-1 T2D trial, weight loss versus injectable semaglutide and tirzepatide, side-effect profile, and Australian timeline implications.
A research overview of how recombinant HGH (somatropin) activates the growth hormone receptor and JAK2/STAT5 signalling to drive hepatic IGF-1 production.
A research-backed explainer on orforglipron (Foundayo) — the first oral small-molecule GLP-1 receptor agonist approved for weight loss, why no-restriction dosing matters, what the ATTAIN trials showed, and how it compares to injectables and oral semaglutide.
A detailed breakdown of the TRIUMPH-1 Phase 3 trial results for retatrutide — the triple-hormone agonist that achieved up to 28.3% mean weight loss at 80 weeks and ~30.3% in a higher-BMI subgroup at 104 weeks.
Cagrilintide is a once-weekly long-acting amylin analog, and Cagrisema combines it with semaglutide. This guide covers the REDEFINE Phase 3 trial results, how amylin co-agonism works, why the headline weight loss disappointed market expectations despite being clinically significant, and what the Australian regulatory path looks like.
Is body recomposition possible? The evidence says yes — under specific conditions. Here's the science behind losing fat and gaining muscle at the same time, including protein targets, training requirements, and realistic timelines.
Why weight loss plateaus happen: adaptive thermogenesis, NEAT decline, leptin changes, the Biggest Loser study, and strategies to break through.
Sub-clinical GLP-1 dosing (semaglutide 0.1–0.25 mg weekly, tirzepatide 1.25–2.5 mg weekly) is rising on cost and tolerability grounds. Here is what STEP 1 titration data, SURMOUNT-1 and the Australian PBS and compounded supply context actually tell us — with the research vs personal-use distinction front and centre.
Men over 50 face a specific cluster of hormonal and metabolic changes that make conventional weight loss advice largely ineffective. This protocol addresses testosterone decline, sarcopenia, insulin resistance, cortisol dysregulation, and slowing metabolism with evidence-based strategies.
A deep-dive into the evidence behind HIIT for weight loss, covering EPOC, appetite effects, insulin sensitivity, beginner and advanced protocols, and why doing too much can backfire.
Compounded semaglutide in Australia: why the TGA banned compounding in 2024, the safety concerns behind it, current legal status, and approved 2026 alternatives.
A science-based research overview of AOD-9604, Tesamorelin, and Semaglutide — how each compound works, what the research shows, how they differ mechanistically, and the Australian regulatory context.
STEP 1 extension data shows roughly two-thirds of lost weight returns within a year of stopping semaglutide. Here is what the research says about why regain happens, taper vs cold stop, maintenance dosing, lifestyle anchors, and the Australian PBS context.
Liraglutide (Saxenda) and semaglutide (Wegovy) are both PBS-listed GLP-1 agonists approved for weight management in Australia. A detailed evidence comparison of efficacy, side effects, dosing, cost, and patient suitability.
Australia obesity statistics 2026: 2 in 3 adults overweight or obese, 1 in 4 children affected, $11.8B economic cost, trends since 1995 and GLP-1 era context.
Understand the science of Zone 2 cardio — how low-intensity training drives fat oxidation, mitochondrial adaptation, and metabolic health improvements, and how much you actually need each week.
Menopause weight gain is driven by specific hormonal and metabolic shifts — not simply ageing or lifestyle. Here's what the evidence says about oestrogen, FSH, GLP-1 medications, MHT, and the interventions that actually work.
Complete guide to Ozempic (semaglutide) in Australia 2026: PBS listing status, cost with and without subsidy, how to access it, supply issues, and how it compares to Wegovy.
A science-based guide to carb cycling for weight loss — how it works, the main protocols, macro calculations, sample meal plans, and how it compares to keto, intermittent fasting, and standard caloric restriction.
A comprehensive guide to tirzepatide (Mounjaro) in Australia — covering TGA approval, PBS status, private prescription costs, SURMOUNT trial results, and how it compares to semaglutide for weight loss.
Facial volume loss and skin laxity on GLP-1 medications is real, but not unique to Ozempic. Here's what drives it and how to reduce the effect.
A deep-dive into the foods, nutrients, and lifestyle factors that stimulate endogenous GLP-1 release — the science behind the 'natural Ozempic' angle, what the evidence actually supports, and a practical daily protocol.
Decades of diet wars have produced a clear answer — and it's not what either side claims. Here's what the best head-to-head trials show about low-carb and low-fat diets for weight loss, metabolic health, and long-term adherence.
Evidence-based guide to protein intake for weight loss — optimal grams per kilogram, timing, satiety mechanisms, and the Australian dietary context. Backed by 2024-2026 research.
Why the standard calorie deficit stops working after 40 for women — perimenopause hormonal cascade, metabolic adaptation, cortisol-driven fat storage, thyroid changes — and a practical, evidence-based protocol to work with your biology.
Everything you need to know about caloric deficit for weight loss — TDEE calculation, safe rate of loss, metabolic adaptation, protein-sparing strategies, and practical tracking methods for Australians.
A detailed evidence-based comparison of tirzepatide vs semaglutide for weight loss in Australia — covering SURMOUNT and SUSTAIN trial data, TGA approval status, PBS eligibility, cost, and who each drug suits in 2026.
Can food and supplements mimic Ozempic's GLP-1 effects? We examine the Stanford 2026 discovery, berberine, fibre, and other 'natural ozempic' claims against the actual evidence.
Why PCOS makes weight loss harder and what research shows actually works — insulin resistance, low GI diet, inositol, metformin, GLP-1 medications, and exercise protocols tailored to PCOS physiology.
Nausea, vomiting, constipation, and fatigue affect up to 40% of GLP-1 agonist users in the first weeks. Here's what causes them, which side effects typically resolve, and the evidence-based strategies that make the difference between staying on treatment and stopping.
Cortisol and weight gain are closely linked through fat storage, appetite disruption, and insulin resistance. Learn the science, the symptoms, and evidence-based strategies to lower cortisol naturally — with Australian context.
A research-backed review of intermittent fasting for weight loss — 16:8, 5:2, and time-restricted eating protocols reviewed against the latest 2025-2026 meta-analyses including the Cochrane review.
How thyroid dysfunction causes weight gain in Australia, what TSH levels mean, the Hashimoto's connection, subclinical hypothyroidism, diet strategies, medications on the PBS, and when to ask your GP for a full thyroid panel.
What insulin resistance is, how to test for it, and the evidence-based strategies that reverse it — diet, exercise, supplements, and medications. The metabolic foundation of sustainable weight loss.
Bariatric surgery outcomes are significantly shaped by pre-operative preparation. Here's the evidence on liver shrinkage diets, nutritional optimisation, exercise capacity, psychological readiness, and what Australian public vs private pathways look like.
Your gut microbiome directly influences how many calories you extract from food, how much fat you store, and how your hunger hormones work. Here is the evidence on restoring microbiome diversity for weight loss.
Wegovy (semaglutide 2.4mg) has been recommended for PBS listing in Australia for chronic weight management. Here's what the PBS decision means for cost, eligibility, and access to semaglutide for weight loss in 2026.
Up to 40% of weight lost on GLP-1 medications like Ozempic and Wegovy can be lean mass. Here's the evidence-based protocol for resistance training, protein intake, and supplementation to protect muscle while maximising fat loss.
Wegovy's PBS listing in 2025 was a watershed moment for obesity medicine in Australia. Here's the full picture of which GLP-1 medications are PBS-listed, eligibility criteria, cost impacts, and what may change with pending PBAC submissions through 2027.
Starvation mode, spot reduction, eating after 8pm — most popular weight loss advice is based on myth, not evidence. Here's what the research actually shows about fat loss, metabolism, and sustainable results.
Visceral fat — the fat around your organs — is metabolically active, drives inflammation, and predicts cardiovascular and metabolic risk far better than BMI. Here's what the evidence says about how to reduce it.
Poor sleep dramatically increases hunger hormones, reduces satiety signals, and drives cravings for high-calorie foods — making dietary adherence nearly impossible. Here's the evidence on sleep's role in weight regulation and how to use sleep as an active weight management tool.
A research review of NAD+ and its role in metabolic regulation, energy production, and whether current evidence supports a role in weight loss — covering sirtuins, AMPK, and precursor research.
How exercise, meal structure, sleep and stress shape your body's own GLP-1 secretion — the lifestyle levers behind natural appetite regulation, and how they compare to pharmaceutical GLP-1 agonists.
A clear explanation of what insulin resistance is, how it develops, why it drives weight gain, and what research shows about reversing it — including the role of GLP-1 agonists.
A research review of HGH Fragment 176-191 — the C-terminal growth hormone fragment studied for its lipolytic effects — covering mechanism, animal data, and what limited human evidence exists.
A research overview of AOD-9604 (HGH Fragment 176-191 as AOD-9604) — its origins, mechanism of lipolytic action, clinical trial history, and current regulatory status.
A clear explanation of how GLP-1 receptor agonists reduce appetite, promote weight loss, and affect blood sugar — covering the biology without unnecessary complexity.
How the three generations of incretin therapy compare on mechanism and trial data — single (semaglutide), dual (tirzepatide), and triple agonism (investigational retatrutide) — and what the TRIUMPH Phase III programme will settle.
A research-backed analysis of the STEP-1 trial data on lean mass changes with semaglutide, and what it means for the media narrative around GLP-1 agonists and muscle loss.